High throughput assay for novel pharmacological probes targeting cAMP signaling
High throughput assay for novel pharmacological probes targeting cAMP signaling
批准号:
7991500
负责人:
XIAODONG CHENG
金额:
$15.3万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2013-06-30
关键词:
AgonistBindingBiochemicalBiological AssayBiological ProcessCellsCyclic AMPCyclic AMP ReceptorsCyclic AMP-Dependent Protein KinasesDiabetes MellitusDimensionsDiseaseEnvironmentEukaryotic CellFluorescenceGoalsGuanine Nucleotide Exchange FactorsGuanine NucleotidesHeart failureIntracellular Second MessengerLeadLibrariesLifeMalignant NeoplasmsMeasuresMediatingMedicalMolecularMolecular ProbesMonitorPhysiologicalPlayProteinsReactionRegulationResearchScreening procedureSecond Messenger SystemsSignal TransductionSpecificitySystemTestingTherapeuticTissuesassay developmentbasedesignhigh throughput screeninginnovationnovelphosphoric diester hydrolasepotency testingprogramspublic health relevanceresearch studysecond messengertool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): cAMP-mediated cell signaling regulates a myriad of important biological processes under both physiological and pathological conditions, including diabetes, heart failure, and cancer. In eukaryotic cells, the effects of cAMP are transduced by two intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (Epac/cAMP-GEF). Like PKA, Epac contains a cAMP-binding domain, an evolutionally conserved structural motif that acts as a molecular switch for sensing intracellular second messenger cAMP levels. The discovery of Epac has opened a new dimension in studying the cAMP-mediated signaling as both PKA and Epac are ubiquitously expressed in all tissues. An increase in intracellular cAMP levels will lead to the activation of both PKA and Epac. Therefore, the net cellular effects of cAMP are not just dictated by PKA or Epac alone, but dependent upon the dynamic expression of Epac and PKA and their specific subcellular distribution in a particular tissue. Currently, the physiological functions of Epac are not clear. One of the major challenges within the research field is the lack of Epac-specific antagonists to dissect the specific physiological functions that Epac play in the overall cAMP-mediated signaling. The objective of this proposal is to develop a High Throughput Screening (HTS) assay for the discovery of novel molecular probes that are specific for Epac but not PKA. These Epac-specific probes will be powerful pharmacological tools for investigating the biological functions of Epac and molecular mechanism of cAMP signaling as well as, for promoting an understanding of disease mechanisms related to Epac/cAMP signaling.
PUBLIC HEALTH RELEVANCE: The goal of our proposed research is to develop a High Throughput Screening assay for the discovery of novel target-specific pharmacological probes that can be used for elucidating the mechanism of signal transduction mediated by an important second messenger, cAMP. The medical and pharmacological implications of this research program are far-reaching. Novel pharmacological probes targeting specific cAMP signaling components can potentially lead to the identification of mechanism-based therapeutic strategies for diseases associated with cAMP signaling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Significance of Epac signaling in renal Na+ handling and hypertension
-
批准号:10864073
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2023
-
负责人:XIAODONG CHENG
-
依托单位:
Epac1 as a novel therapeutic target for diabetic retinopathy
-
批准号:10689112
-
项目类别:
-
资助金额:$50.62万
-
财政年份:2022
-
负责人:XIAODONG CHENG
-
依托单位:
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
-
批准号:10198941
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2017
-
负责人:XIAODONG CHENG
-
依托单位:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
-
批准号:9250048
-
项目类别:
-
资助金额:$120.96万
-
财政年份:2014
-
负责人:XIAODONG CHENG
-
依托单位:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
-
批准号:9038248
-
项目类别:
-
资助金额:$125.62万
-
财政年份:2014
-
负责人:XIAODONG CHENG
-
依托单位:
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
-
批准号:8694342
-
项目类别:
-
资助金额:$153.87万
-
财政年份:2014
-
负责人:XIAODONG CHENG
-
依托单位:
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)
-
批准号:8482964
-
项目类别:
-
资助金额:$49.11万
-
财政年份:2013
-
负责人:XIAODONG CHENG
-
依托单位:
High throughput assay for novel pharmacological probes targeting cAMP signaling
-
批准号:8477859
-
项目类别:
-
资助金额:$3.83万
-
财政年份:2010
-
负责人:XIAODONG CHENG
-
依托单位:
Genetic Screening:Oncogene RAS-Based Inhibi*(RMI)
-
批准号:7058055
-
项目类别:
-
资助金额:$0.45万
-
财政年份:2005
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:6743684
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:6888183
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:7994210
-
项目类别:
-
资助金额:$34.39万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:9260012
-
项目类别:
-
资助金额:$37.26万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:7238664
-
项目类别:
-
资助金额:$25.71万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:8762253
-
项目类别:
-
资助金额:$39.57万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:7583771
-
项目类别:
-
资助金额:$35.8万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:8783945
-
项目类别:
-
资助金额:$23.42万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:8387786
-
项目类别:
-
资助金额:$9.56万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:8197449
-
项目类别:
-
资助金额:$34.46万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
-
批准号:7059367
-
项目类别:
-
资助金额:$26.48万
-
财政年份:2003
-
负责人:XIAODONG CHENG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: